Q1 2022 Results
Company overview
Financial review
Financial performance
CRM
Immunology
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
Appendix
References
Innovation: Clinical trials
Abbreviations
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Tafinlar + MekinistⓇ - BRAF inhibitor and MEK inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
Read-out Milestone(s)
Publication
NCT02684058 (CDRB436G2201)
BRAFV600 mutant gliomas
Phase 2
142
Objective response rate
Dabrafenib + trametinib (dose based on age and weight)
Children and adolescent patients with BRAF V600 mutation positive relapsed or
refractory high grade glioma (HGG) or BRAF V600 mutation positive low grade
glioma (LGG)
Q4 2021 (actual)
TBD
100 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation